Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / IL6R



This biomarker is also known as:
  • gp80,
  • IL-6R 1,
  • OTTHUMP00000217870,
  • CD126,
  • IL6RA,
  • interleukin-6 receptor subunit alpha,
  • IL-6R-1,
  • MGC104991,
  • IL-6R-alpha,
  • IL-6R subunit alpha,
  • CD126 antigen,
  • interleukin 6 receptor alpha subunit,
  • interleukin 6 receptor,
  • Membrane glycoprotein 80,
  • IL-6 receptor subunit alpha,
  • IL-6RA,

View in BioMuta


The interleukin 6 receptor is a protein complex consisting of two parts: the IL6R (interleukin 6 receptor) subunit and the IL6ST (interleukin 6 signal transducer) subunit. The IL6R subunit binds to IL6 (interleukin 6) with low affinity, but does not transduce a signal. The IL6ST subunit is needed for signal activation. Impaired regulation of IL6 and IL6R have been linked to many diseases, such as multiple myeloma, autoimmune diseases, and prostate cancer. Isoforms encoded by alternatively spliced transcripts have been reported. Activation of the IL6/IL6R/IL6ST complex may lead to the regulation of the immune response, acute-phase reactions, and hematopoiesis.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


IL6R alone has not been found to be a strong predictor of ovarian cancer.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014

Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.